Aktuellt
SENASTE
The strong recovery of the core Thoracic core business is especially reassuring in our view, with organic growth of 33% in Q4. The Abdominal division continues to deliver near 30% organic growth. Together with improved gross margins for both divisions, the Q4 is distinctly positive in our view. We regard this as a good entry into 2022, a year supported by the US Kidney Assist Transport launch and the Star acquisition, as well as an easing risk of COVID related distractions.
LÄS MER
